PHASE I/II AND PHARMACOLOGIC STUDYOF PACLITAXEL GIVEN AS 96 HOUR INFUSION

紫杉醇 96 小时输注的 I/II 期和药理学研究

• 批准号: 6246776
• 负责人: Barbara A. Murphy
• 金额: $ 3.1万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-27 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246776
• 关键词: cis platinum compound; clinical research; combination chemotherapy; drug administration rate /duration; drug adverse effect; head /neck neoplasm; human subject; human therapy evaluation; injection /infusion; neoplasm /cancer pharmacology; paclitaxel; pharmacokinetics

To determine the maximum tolerated doses of paclitaxel given as a 96 hour infusion in combination with cisplatin in patients with advanced head and neck cancer. To document the type, frequency, and severity of toxicities associated with combination chemotherapy using prolonged infusion paclitaxel and cisplatin. To study the clinical pharmacology of paclitaxel when administered on this schedule and seek pharmacokinetic correlates with clinical endpoints.

为了确定紫杉醇的最大耐受剂量， 24小时静脉滴注联合顺铂治疗晚期乳腺癌 头颈癌 记录以下事件的类型、频率和严重程度： 与联合化疗相关的毒性， 输注紫杉醇和顺铂。 临床药理学研究 紫杉醇的剂量，并寻求 药代动力学与临床终点相关。